Scientific Advisory Board AgreementScientific Advisory Board Agreement • March 7th, 2018 • IASO BioMed, Inc. • Pharmaceutical preparations • Colorado
This Scientific Advisory Board Agreement (the “Agreement”), shall be effective as of March 1, 2018 (the “Effective Date”), and is entered into by IASO BioMed Inc., with a business address at 7315 East Peakview Ave., Centennial, CO 80111, USA (the “Company”), and Dr. Costas Karatzas personally or through CNKonsulting with a business address at _____________________________ (the “Advisor”).
EXECUTIVE EMPLOYMENT AND NON-COMPETE AGREEMENTExecutive Employment and Non-Compete Agreement • March 24th, 2017 • IASO BioMed, Inc. • Pharmaceutical preparations • Colorado
THIS AGREEMENT (this “Agreement”) is dated this 1st day of March, 2017 (the “Effective Date”), by and between IASO BioMed, Inc., a Colorado corporation with offices at 7315 East Peakview Ave., Centennial, Colorado 80111 (the “Company”), and Richard M. Schell, (“Executive”).
SUBSCRIPTION AGREEMENT IASO BioMed, Inc. 7315 East Peakview Avenue Centennial, Colorado 80111 Private Placement Units Consisting of One Share of Common Stock and One WarrantSubscription Agreement • July 25th, 2017 • IASO BioMed, Inc. • Pharmaceutical preparations • Colorado
The undersigned understands that IASO BioMed, Inc., incorporated under the laws of the State of Colorado (the “Company”), is offering units (each, a “Unit”) with each Unit consisting of one (1) share of common stock, par value $0.0001, of the Company (the “Common Stock” and a warrant (the “Warrant”) to purchase one (1) share of Common Stock, at an exercise price of $.01 per share, expiring three (3) years from the date hereof (the “Offering”) to the undersigned pursuant to the terms of this Subscription Agreement. The Unit, together with the Common Stock issued thereunder, the Warrant and the Common Stock issuable upon the exercise of the Warrant are referred to as the “Securities”).The undersigned further understands that (i) the Offering is being made without registration of the Securities under the Securities Act of 1933, as amended (the “Securities Act”), and is being made only to “accredited investors” (as defined in Rule 501(a) of Regulation D under the Securities Act) under an e
RESEARCH AGREEMENTResearch Agreement • February 1st, 2017 • IASO BioMed, Inc. • Pharmaceutical preparations • Quebec
THIS AGREEMENT, effective as of the date of the last duly authorized signature below (the “Effective Date”), is entered into by and among IASO BioMed, Inc., with a place of business located at 7315 East Peakview Avenue, Centennial, Colorado 80111 (“IASO BioMed, Inc.”), The Research Institute of the McGill University Health Centre, with an address of 2155 Guy Street, Suite 500, Montreal QC H3H 2R9 (the “Institution”) and Dr. Vassilios Papadopoulos, with an address of The Research Institute of the McGill University Health Centre, 1001 Decarie Blvd., Bloc E, Montreal QC H4A 3J1 (the “Principal Investigator”), governing a research study entitled: “Peptide-based pharmacological induction of androgen formation in male hypogonadism” (the “Study” or “Research Program”), to be conducted by the Principal Investigator at the Institution. IASO BioMed, Inc., Institution, and Principal Investigator shall collectively be referred to as “parties” and individually as a “party”.
AMENDMENT TO THE RESEARCH AGREEMENT BETWEEN IASO BIOMED US INC., AND THE RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTREResearch Agreement • March 24th, 2017 • IASO BioMed, Inc. • Pharmaceutical preparations • Quebec
This Amendment Number One (this “Amendment”), effective January 8, 2017, to the Research Agreement between IASO Biomed, Inc., and the Research institute of the McGill University Health Centre, effective January 8, 2016,
AMENDMENT TO THE RESEARCH AGREEMENT BETWEEN IASO BIOMED US INC., AND THE RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTREResearch Agreement • April 24th, 2019 • IASO BioMed, Inc. • Pharmaceutical preparations • Quebec
This Amendment Number Two (this “Amendment”) to the Research Agreement between IASO Biomed, Inc. and the Research Institute of the McGill University Health Centre, effective January 8, 2016
STANDARD LICENSE AGREEMENT (Spin-off)License Agreement • February 15th, 2017 • IASO BioMed, Inc. • Pharmaceutical preparations
Consulting AgreementConsulting Agreement • March 7th, 2018 • IASO BioMed, Inc. • Pharmaceutical preparations • Colorado
THIS CONSULTING AGREEMENT (the “Agreement”), effective as of March 1, 2018, is entered into by and between Iaso BioMed, Inc., a Colorado corporation (“Company”), and Thomas B. Olson, personally, or through Cresthill Associates, LLC, a Colorado Limited Liability Corporation, his single-member LLC (together the “Consultant”).
Iaso BioMed, Inc. Consulting AgreementConsulting Agreement • September 23rd, 2019 • IASO BioMed, Inc. • Pharmaceutical preparations • Colorado
This Consulting Agreement (“Agreement”) is made as of the 17 day of September 2019 between IASO BioMed, Inc. (the “Company”) having an address at 7315 East Peakview Avenue, Centennial, CO 80111, United States and Doug Morris having and address at _____________________________________.
PUBLIC OFFERING SUBSCRIPTION AGREEMENTPublic Offering Subscription Agreement • April 16th, 2018 • IASO BioMed, Inc. • Pharmaceutical preparations • Colorado
FOR MORE INFORMATION ON THE OFFERING, PLEASE SEE SCHEDULE A BEGINNING ON PAGE 3. FOR A COMPLETE DESCRIPTION OF THE PUBLIC OFFERING AND INFORMATION REGARDING INVESTMENT RISKS, YOU ARE URGED TO READ THE PROSPECTUS.
